Citigroup Initiates Coverage On Mirum Pharmaceuticals with Buy Rating, Announces Price Target of $145
Benzinga Newsdesk 5 months ago
NewsPrice TargetInitiationAnalyst Ratings
Citigroup analyst Yigal Nochomovitz initiates coverage on Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy rating and announces Price Target of $145.
Citigroup analyst Yigal Nochomovitz initiates coverage on Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy rating and announces Price Target of $145.